FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer.
Sonia ZaghdoudiEmilie DecaupIsmahane BelhabibRémi SamainStéphanie Cassant-SourdyJulia RochotteAlexia BrunelDavid SchlaepferJérome CrosCindy NeuzilletManon StrehaianoAmandine AlardRichard TomasiniVinothini RajeeveAurélie PerraudMuriel MathonnetOliver Mt PearceYvan MartineauStéphane PyronnetCorinne BousquetChristine JeanPublished in: EMBO molecular medicine (2020)
Cancer-associated fibroblasts (CAFs) are considered the most abundant type of stromal cells in pancreatic ductal adenocarcinoma (PDAC), playing a critical role in tumour progression and chemoresistance; however, a druggable target on CAFs has not yet been identified. Here we report that focal adhesion kinase (FAK) activity (evaluated based on 397 tyrosine phosphorylation level) in CAFs is highly increased compared to its activity in fibroblasts from healthy pancreas. Fibroblastic FAK activity is an independent prognostic marker for disease-free and overall survival of PDAC patients (cohort of 120 PDAC samples). Genetic inactivation of FAK within fibroblasts (FAK kinase-dead, KD) reduces fibrosis and immunosuppressive cell number within primary tumours and dramatically decreases tumour spread. FAK pharmacologic or genetic inactivation reduces fibroblast migration/invasion, decreases extracellular matrix (ECM) expression and deposition by CAFs, modifies ECM track generation and negatively impacts M2 macrophage polarization and migration. Thus, FAK activity within CAFs appears as an independent PDAC prognostic marker and a druggable driver of tumour cell invasion.
Keyphrases
- extracellular matrix
- cell migration
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- escherichia coli
- protein kinase
- ejection fraction
- long non coding rna
- mesenchymal stem cells
- bone marrow
- cell therapy
- copy number
- pseudomonas aeruginosa
- dna methylation
- liver fibrosis